GILEAD SCIENCES INC (GILD)       87.83  +2.07 (+2.41%)

87.83  +2.07 (+2.41%)

US3755581036 - Common Stock - After market: 87.83 0 (0%)

GILEAD SCIENCES INC87.83

NASDAQ:GILD (11/30/2022, 7:00:01 PM)+2.07 (+2.41%)

After market: 87.83 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 10-27 2022-10-27/amc Earnings (Next) 01-30 2023-01-30
Ins Owners 0.04% Inst Owners 79.59%
Market Cap 110.16B Shares 1.25B
PE 13.96 Fwd PE 13.37
Dividend Yield 3.49% Analysts 73.51
IPO 01-22 1992-01-22

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GILD Daily chart

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 14,400 full-time employees. The firm is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The firm also sells and distributes generic versions of Epclusa and Harvoni in the United States. The firm is also focused on restoring immune balance with agonists targeting immune inhibitory receptors.

Company Info

GILEAD SCIENCES INC

333 Lakeside Dr

Foster City CALIFORNIA 94404

P: 16505743000.0

CEO: Daniel P. O'Day

Employees: 14400

Website: https://www.gilead.com/

GILD News

News Image10 hours ago - Market News VideoIntuit Takes Over #73 Spot From Gilead SciencesNews Image11 hours ago - Yahoo FinanceUPDATE 1-FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab

Eli Lilly and Co's COVID-19 drug bebtelovimab is not currently authorized for emergency use in the United States, the Food and Drug Administration said, citing it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron. Wednesday's announcement takes away authorization from the last COVID-19 monoclonal antibody treatment, leaving Pfizer Inc's antiviral drug Paxlovid, Merck's Lagevrio and Gilead Sciences' Veklury as treatments for the disease, besides convalescent plasma for some patients. AstraZeneca Plc's monoclonal antibody Evusheld is also authorized for protection against COVID-19 infection in some people.

News Image18 hours ago - The Motley Fool2 Reasons This Stock Could Outperform in 2023

It would be a continuation of this year's showing.

News Image21 hours ago - The Motley FoolThese 3 Stocks Are Rallying While the Rest of the Market Plunges

Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds.

News Image2 days ago - Seeking AlphaGilead gets European approval for use of HIV drug Biktarvy in children

Gilead Sciences (GILD) on Tuesday said the European Commission had approved an expansion for its HIV drug Biktarvy for the use in children

News Image2 days ago - Gilead Sciences, Inc.European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations

GILD Twits

Here you can normally see the latest stock twits on GILD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example